Howard Morse

Cooley advised Vision Government Solutions, a portfolio company of Rubicon Technology Partners and a leader in the appraisal, computer-assisted mass appraisal and property tax industry, on its majority recapitalization with Great Hill Partners.

Cooley advised Egnyte, a provider of secure content collaboration and governance solutions, on its strategic growth investment from GI Partners and TA Associates.

Cooley advised Harvey, a domain-specific artificial intelligence (AI) platform for legal and professional services, on its $300 million Series D financing at a $3 billion valuation.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.